HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bortolotti, U. Articles by Gallucci, V. Search for Related Content PubMed PubMed Citation Articles by Bortolotti, U. Articles by Gallucci, V.

European Journal of Cardio-Thoracic Surgery, Vol 2, 458-464, Copyright © 1988 by European Association for Cardio-thoracic Surgery

ARTICLES

The Hancock pericardial xenograft: incidence of early mechanical failures at a medium-term follow-up

U Bortolotti, A Milano, A Mazzucco, F Guerra, M Valente, G Thiene, E Talenti and V Gallucci
Department of Cardiovascular Surgery, University of Padova Medical School, Italy.

The Hancock pericardial xenograft has been used in our Institution since August 1981 as an alternative to porcine bioprostheses. Up to July 1984, 97 Hancock pericardial xenografts have been implanted in 84 patients; of 76 operative survivors with a mean age of 55.2 +/- 13 years (range 13-75 years), 50 had undergone aortic valve replacement, 16 mitral valve replacement and 10 mitral-aortic valve replacement. Follow-up ranged from 0.5 to 5.2 years with a cumulative duration of 239 patient/years and is 99% complete. Actuarial survival is 92% +/- 4% for patients with aortic valve replacement and 84% +/- 10% for patients with mitral valve replacement at 5 years, and 77% +/- 14% for those with mitral-aortic valve replacement at 4 years. Thromboembolic episodes occurred in 2 patients (1 after aortic and 1 after mitral valve replacement). The actuarial freedom from emboli is 100% for patients with mitral-aortic valve replacement at 4 years, and 96% +/- 3% for patients with aortic and 93% +/- 6% for patients with mitral valve replacement at 5 years. Reoperation was performed in 13 patients (9 aortic, 2 mitral and 2 mitral-aortic valve replacements), because of endocarditis in 3 (2 aortic and 1 mitral valve replacement), paravalvular leak in 1 (aortic valve replacement), and primary tissue failure in 9 (6 aortic, 1 mitral and 2 mitral-aortic valve replacements). Actuarial freedom from primary tissue failure is 72% +/- 9% for aortic and 83% +/- 8% for mitral Hancock pericardial xenografts at 5 years. Eleven xenografts explanted because of primary tissue failure were studied pathologically.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J. M. Garcia Paez, A. Carrera, A. Cordon, E. Jorge-Herrero, A. Rocha, J. Salvador, J. Mendez, J. L. Castillo-Olivares, I. Millaan, and N. Sainz Uniaxial and Biaxial Tensile Strength of Calf Pericardium Used in the Construction of Bioprostheses: Biomaterial Selection Criteria J Biomater Appl, July 1, 2000; 15(1): 47 - 64. [Abstract] [PDF]

				U. Bortolotti, G. Scioti, A. Milano, M. De Carlo, R. Codecasa, C. Nardi, and G. Tartarini Performance of 21-mm size perimount aortic bioprosthesis in the elderly Ann. Thorac. Surg., January 1, 2000; 69(1): 47 - 50. [Abstract] [Full Text] [PDF]

				T. A. Orszulak, H. V. Schaff, C. J. Mullany, B. J. Anderson, D. M. Ilstrup, F. J. Puga, and G. K. Danielson Risk of Thromboembolism With the Aortic Carpentier-Edwards Bioprosthesis Ann. Thorac. Surg., February 1, 1995; 59(2): 462 - 468. [Abstract] [Full Text]